Table 2.
Summary of sRAGE, esRAGE, and CIMT Results
| Variable [Median (Q1, Q3) or N (%)] | Group | |||||
|---|---|---|---|---|---|---|
| Total (N=80) | HIV/PI (N=25) | HIV/not PI (N=21) | not HIV (N=34) | Combined HIV (N=46) | P-Value | |
| Week 0 sRAGE (pg/mL) | 1,039 (797, 1,298) | 1,053 (779, 1,450) | 1,075 (820, 1,416) | 1,030 (797, 1,265) | 1,064 (792, 1,433) | 0.81 a |
| Week 72 sRAGE (pg/mL) | 1,062 (835, 1,468) | 1,006 (840, 1,427) | 1,103 (880, 1,534) | 1,069 (830, 1,458) | 1,033 (840, 1,478) | 0.85 a |
| Week 96/144 sRAGE (pg/mL) | 1,136 (805, 1,565) | 1,327 (708, 1,823) | 1,128 (936, 1,507) | 990 (758, 1,561) | 1,162 (852, 1,658) | 0.65 a |
| Yearly Rate of Change in sRAGE (per pg/mL/yr) | 32 (−43, 99) | 35 (−46, 157) | 33 (−40, 81) | 24 (−42, 92) | 34 (−46, 114) | 0.60 b; 0.08 c |
| P-Value d | 0.07 | 0.25 | 0.14 | 0.05 | ||
|
| ||||||
| Week 0 esRAGE (pg/mL) | 233 (139, 337) | 213 (143, 343) | 234 (145, 314) | 236 (128, 343) | 229 (143, 331) | 0.95 a |
| Week 72 esRAGE (pg/mL) | 299 (175, 478) | 220 (155, 471) | 301 (171, 421) | 327 (207, 481) | 266 (156, 471) | 0.74 a |
| Week 96/144 esRAGE (pg/mL) | 362 (231, 538) | 377 (218, 663) | 351 (257, 437) | 350 (234, 565) | 374, 219, 527) | 0.86 a |
| Yearly Rate of Change in esRAGE (per pg/mL/yr) | 43 (9, 72) | 57 (15, 107) | 41 (−5, 64) | 43 (19, 66) | 44 (−2, 74) | 0.17 e; 0.08 f |
| P-Value d | <0.001 | 0.004 | <0.001 | <0.001 | ||
|
| ||||||
| Progression of CIMT (≥ 12.2 μm/yr) | 30 (38%) | 13 (52%) | 4 (19%) | 13 (38%) | 17 (37%) | 0.08g |
| Yearly Rate of Change in CIMT(μm/y) | 9 (1, 14) | 13 (1, 16) | 6 (−7, 10) | 9 (4, 15) | 8 (−2, 13) | 0.87 h; 0.12 i |
| P-Value d | <0.001 | 0.43 | <0.001 | 0.002 | ||
Kruskal-Wallis Test testing the difference among the HIV/PI, HIV/not PI, and not HIV groups.
Wilcoxon Test for matched group differences within each visit week testing HIV versus not HIV (“HIV effect”; N=29 matched pairs/triplets).
Wilcoxon Test for matched group differences within each visit week testing PI versus not PI (“PI effect”; N=11 matched pairs). The median (Q1, Q3) of the paired differences was 52 (−22, 282) pg/mL/yr.
Wilcoxon Test for zero yearly rate of change within each group.
Wilcoxon Test for matched group differences within each visit week testing HIV versus not HIV (“HIV effect”; N=29 matched pairs/triplets).
Wilcoxon Test for matched group differences within each visit week testing PI versus not PI (“PI effect”; N=11 matched pairs). The median (Q1, Q3) of paired differences was 66 (8, 89) pg/mL/yr.
Fisher’s Exact Test.
Wilcoxon Test for matched group differences within each week testing HIV versus not HIV (“HIV effect”; N=29 matched pairs/triplets).
Wilcoxon Test for matched group differences within each week testing HIV/PI versus HIV/not PI (“PI effect”; N=11 matched pairings).